Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CVS Health Corporation : Good timing to anticipate a continuation of the trend

06/18/2021 | 02:44am EDT
long trade
Stop-loss triggered
Entry price : 83.52$ | Target : 89.85$ | Stop-loss : 81.2$ | Potential : 7.58%
Shares in CVS Health Corporation show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the $ 89.85.
CVS Health Corporation : CVS Health Corporation : Good timing to anticipate a continuation of the trend
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

  • The company shows low valuation levels, with an enterprise value at 0.57 times its sales.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Historically, the company has been releasing figures that are above expectations.

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company does not generate enough profits, which is an alarming weak point.

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 282 B - -
Net income 2021 8 233 M - -
Net Debt 2021 48 413 M - -
P/E ratio 2021 13,4x
Yield 2021 2,40%
Capitalization 110 B 110 B -
EV / Sales 2021 0,56x
EV / Sales 2022 0,52x
Nbr of Employees 256 500
Free-Float 75,6%
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 83,30 $
Average target price 95,94 $
Spread / Average Target 15,2%
EPS Revisions
Managers and Directors
Karen S. Lynch President, Chief Executive Officer & Director
Shawn M. Guertin Chief Financial Officer & Executive Vice President
David Wyatt Dorman Chairman
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Jonathan C. Roberts Chief Operating Officer & Executive Vice President